The overexpression and aberrant expression of HER2/neu is seen in some ovarian, prostate, gastric, and lung cancers [81], but it is most prevalent in breast cancer, with ~30% of tumours overexpressing HER2 [82]. This evidence concerns the gene ERBB2 and lung cancer.